# Antibody trials that enrol mixed and comorbid disease

Source: https://onco.cc/ideas/da-idea-inclusive-anti-amyloid-trials/  
OnCo record `da-idea-inclusive-anti-amyloid-trials` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Test amyloid antibodies in the mixed, comorbid people clinics actually see, instead of only in tidy trial cohorts.

## Summary

Until that trial exists, labels and MRI rules should stay conservative. This idea is a proposed test, not a reason to ignore exclusions.

## Fields

- Kind: Idea
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Hypothesis: A pragmatic trial in people with mixed pathology or common comorbidities can show whether antibody benefit and ARIA risk still justify treatment outside the original label population.
- Rationale: Current phase 3 cohorts are cleaner than clinic. Access decisions still hit mixed disease.
- Proposed test: Registry-based randomised or well-controlled observational comparison with ARIA and function as co-primary, stratified by vascular burden and anticoagulation.
- Maturity: speculative
- Actor: research

## Sources

- ClinicalTrials.gov: https://clinicaltrials.gov

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mixed dementia](https://onco.cc/diagnoses/mixed-dementia/)
- drugs: [Donanemab](https://onco.cc/drugs/da-donanemab/), [Lecanemab](https://onco.cc/drugs/da-lecanemab/)
- bottlenecks: [Trial populations that skip mixed disease](https://onco.cc/bottlenecks/da-bn-trial-exclusion/)

---
JSON: https://onco.cc/api/v1/entities/da-idea-inclusive-anti-amyloid-trials.json